PL_GNT01_ISR_Grant 53234273
Launched by NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND · Nov 27, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Demographic information, TTR genotype, medical history, family history of the disease, and transplant history are assessed at baseline. On return visits, signs and symptoms of the disease are evaluated, general examinations are conducted, and laboratory data, measures of neurologic and cardiovascular function, and quality of life are assessed according to the standard of care for patients.
Specific Aims and Hypotheses
Our working hypotheses are:
1. TTR amyloidosis affects patients in the population of our country;
2. there are specific TTR mutations in the population of our country;
3. t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults over 18 years old with confirmed diagnosis of TTR amyloidosis
- Exclusion Criteria:
- • Refusal to participate in the study. Light-chain amyloidosis.
About National Institute Of Cardiology, Warsaw, Poland
The National Institute of Cardiology in Warsaw, Poland, is a leading research institution dedicated to advancing the understanding and treatment of cardiovascular diseases. Renowned for its commitment to innovative clinical research, the Institute focuses on improving patient outcomes through comprehensive studies that encompass prevention, diagnosis, and therapeutic strategies. With a multidisciplinary team of experts and state-of-the-art facilities, the National Institute of Cardiology plays a pivotal role in contributing to global cardiovascular knowledge and enhancing clinical practices in the field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported